Showing 3421-3430 of 6035 results for "".
- BVI’s Podeye Hydrophobic Monofocal IOL Launched in Japanhttps://modernod.com/news/bvis-podeye-hydrophobic-monofocal-iol-launched-in-japan/2482239/BVI Medical announced the launch of the Podeye hydrophobic monofocal intraocular lenses (IOL) in Japan after receiving approval by the Japanese Pharmaceuticals and Medical Devices Agency. Podeye is now available for commercial use and available to surgeons across the country. The Podeye
- Aviceda Therapeutics Announces Formation of European Clinical Advisory Boardhttps://modernod.com/news/aviceda-therapeutics-announces-formation-of-european-clinical-advisory-board/2482218/Aviceda Therapeutics announced the formation of its European Clinical Advisory Board (CAB) made up of internationally recognized thought leaders in retina. The CAB will provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geog
- Aldeyra Plans to Resubmit New Drug Application for Reproxalap in Dry Eye Diseasehttps://modernod.com/news/aldeyra-plans-to-resubmit-new-drug-application-for-reproxalap-in-dry-eye-disease/2482193/About 4 months after receiving a complete response letter (CRL) from the FDA, Aldeyra Therapeutics announced a clinical development plan intended to enable resubmission of a new drug application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry
- Alcon Launches Clareon Presbyopia Correcting IOLs in Indiahttps://modernod.com/news/alcon-launches-clareon-presbyopia-correcting-iols-in-india/2482160/Alcon announced the launch of the Clareon family of IOLs in India. Clareon is designed to deliver consistent visual outcomes and exceptional clarity that lasts and is features a glistening-free IOL material that has among the lowest levels of haze and subsurface nanoglist
- New Study Shows Eylea HD with Extended 12- or 16-Week Dosing Demonstrated Noninferior Vision Gains to Standard of Care Eyleahttps://modernod.com/news/lancet-study-eylea-hd-with-extended-12-or-16-week-dosing-demonstrated-noninferior-vision-gains-to-standard-of-care-eylea/2482151/Regeneron announced The Lancet published 1-year results from the pivotal PULSAR and
- Vital Tears Appoints Joseph Tauber, MD, as Chief Medical Officerhttps://modernod.com/news/vital-tears-appoints-joseph-tauber-md-as-chief-medical-officer/2482146/Vital Tears, a provider of autologous serum tears, has announced the appointment of Joseph Tauber, MD, as its Chief Medical Officer (CMO). In his new role, Dr. Tauber will lead Vital Tears’ research and development initiatives, provide physician education and training, and&nb
- Oculis Provides Updates on Late-Stage Clinical Trials; Announces Leadership Appointmentshttps://modernod.com/news/oculis-provides-updates-on-late-stage-clinical-trials-announces-leadership-appointments/2482135/Oculis provided updates its late-stage clinical trials, and also announced senior appointments to its management and advisory teams. The announcements were made during it R&D Day on Wednesday, February 28. “2024 promises to be another exciting year for Ocu
- WashU Awarded up to $20M to Create Portable Device to Scan for Eye Diseaseshttps://modernod.com/news/washu-awarded-up-to-20m-to-create-portable-device-to-scan-for-eye-diseases/2482115/Chao Zhou, a professor of biomedical engineering in the McKelvey School of Engineering at Washington University in St. Louis, has been working to improve optical coherence tomography (OCT) systems that can conduct high-resolution imaging of the eyes. Now, with an up to $20 million contract from t
- Ace Vision Group Names Val Kolesnitchenko, MD, as Chief Scientific Officerhttps://modernod.com/news/ace-vision-group-names-val-kolesnitchenko-md-as-chief-scientific-officer/2482095/Ace Vision Group announced that it has named Val Kolesnitchenko, MD, as Chief Scientific Officer. Dr. Kolesnitchenko has served in leadership roles for three decades in clinical ophthalmology practice and industry. Most recently, he held the position of Executive Director of Global
- Claris Bio Advances Corneal Healing Product Candidate; Secures New Fundinghttps://modernod.com/news/claris-bio-developer-of-corneal-healing-product-candidate-names-new-investor/2482042/Claris Bio unveiled the company and its lead program with a total of $57 million invested. Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye dise